Clinical Trial Update: AFIX to Improve HPV Vaccination [NA]

View source ↗

Summary

The University of North Carolina, Chapel Hill trial evaluated the AFIX quality-improvement approach to increase HPV vaccination uptake and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Intraepithelial Neoplasia
• Genital Warts
• Human Papillomavirus Infection

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Papillomavirus Vaccines, Adolescent Health Services | NA | Status: COMPLETED